![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GKAP1 |
Gene summary for GKAP1 |
![]() |
Gene information | Species | Human | Gene symbol | GKAP1 | Gene ID | 80318 |
Gene name | G kinase anchoring protein 1 | |
Gene Alias | FKSG21 | |
Cytomap | 9q21.32 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q5VSY0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
80318 | GKAP1 | S43 | Human | Liver | Cirrhotic | 2.23e-02 | -1.24e-01 | -0.0187 |
80318 | GKAP1 | HCC1_Meng | Human | Liver | HCC | 4.80e-48 | -9.31e-02 | 0.0246 |
80318 | GKAP1 | HCC2_Meng | Human | Liver | HCC | 2.90e-03 | -9.28e-02 | 0.0107 |
80318 | GKAP1 | HCC1 | Human | Liver | HCC | 1.71e-05 | 1.16e+00 | 0.5336 |
80318 | GKAP1 | HCC5 | Human | Liver | HCC | 1.15e-05 | 1.20e-01 | 0.4932 |
80318 | GKAP1 | S028 | Human | Liver | HCC | 8.57e-03 | 3.37e-01 | 0.2503 |
80318 | GKAP1 | S029 | Human | Liver | HCC | 2.94e-07 | 5.61e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | ![]() |
Stomach | SIM | ![]() |
Liver | NAFLD | ![]() |
Liver | Cirrhotic | ![]() |
Liver | HCC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004343412 | Liver | Cirrhotic | response to peptide hormone | 149/4634 | 414/18723 | 1.70e-07 | 4.49e-06 | 149 |
GO:007137511 | Liver | Cirrhotic | cellular response to peptide hormone stimulus | 110/4634 | 290/18723 | 3.73e-07 | 8.82e-06 | 110 |
GO:190165311 | Liver | Cirrhotic | cellular response to peptide | 129/4634 | 359/18723 | 1.23e-06 | 2.49e-05 | 129 |
GO:003286911 | Liver | Cirrhotic | cellular response to insulin stimulus | 80/4634 | 203/18723 | 2.55e-06 | 4.63e-05 | 80 |
GO:003286811 | Liver | Cirrhotic | response to insulin | 95/4634 | 264/18723 | 2.77e-05 | 3.54e-04 | 95 |
GO:19000782 | Liver | Cirrhotic | positive regulation of cellular response to insulin stimulus | 15/4634 | 25/18723 | 1.88e-04 | 1.75e-03 | 15 |
GO:000828611 | Liver | Cirrhotic | insulin receptor signaling pathway | 44/4634 | 116/18723 | 1.09e-03 | 7.59e-03 | 44 |
GO:0046628 | Liver | Cirrhotic | positive regulation of insulin receptor signaling pathway | 12/4634 | 22/18723 | 2.61e-03 | 1.53e-02 | 12 |
GO:19000761 | Liver | Cirrhotic | regulation of cellular response to insulin stimulus | 26/4634 | 64/18723 | 3.69e-03 | 2.03e-02 | 26 |
GO:003286821 | Liver | HCC | response to insulin | 172/7958 | 264/18723 | 7.14e-14 | 4.23e-12 | 172 |
GO:003286921 | Liver | HCC | cellular response to insulin stimulus | 137/7958 | 203/18723 | 4.69e-13 | 2.44e-11 | 137 |
GO:004343422 | Liver | HCC | response to peptide hormone | 247/7958 | 414/18723 | 9.55e-13 | 4.77e-11 | 247 |
GO:007137521 | Liver | HCC | cellular response to peptide hormone stimulus | 179/7958 | 290/18723 | 2.54e-11 | 9.88e-10 | 179 |
GO:190165321 | Liver | HCC | cellular response to peptide | 211/7958 | 359/18723 | 2.86e-10 | 9.63e-09 | 211 |
GO:00082862 | Liver | HCC | insulin receptor signaling pathway | 78/7958 | 116/18723 | 6.15e-08 | 1.29e-06 | 78 |
GO:19000762 | Liver | HCC | regulation of cellular response to insulin stimulus | 43/7958 | 64/18723 | 5.73e-05 | 5.31e-04 | 43 |
GO:190007811 | Liver | HCC | positive regulation of cellular response to insulin stimulus | 20/7958 | 25/18723 | 1.47e-04 | 1.18e-03 | 20 |
GO:00466261 | Liver | HCC | regulation of insulin receptor signaling pathway | 43/7958 | 66/18723 | 1.69e-04 | 1.34e-03 | 43 |
GO:00466281 | Liver | HCC | positive regulation of insulin receptor signaling pathway | 17/7958 | 22/18723 | 9.84e-04 | 5.70e-03 | 17 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GKAP1 | SNV | Missense_Mutation | c.973N>G | p.Gln325Glu | p.Q325E | Q5VSY0 | protein_coding | tolerated(0.28) | probably_damaging(0.994) | TCGA-A8-A09I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
GKAP1 | SNV | Missense_Mutation | c.197A>G | p.Gln66Arg | p.Q66R | Q5VSY0 | protein_coding | deleterious(0) | possibly_damaging(0.765) | TCGA-HG-A2PA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | Taxol | PD | |
GKAP1 | SNV | Missense_Mutation | c.196C>A | p.Gln66Lys | p.Q66K | Q5VSY0 | protein_coding | tolerated(0.06) | possibly_damaging(0.547) | TCGA-HG-A2PA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | Taxol | PD | |
GKAP1 | SNV | Missense_Mutation | novel | c.955A>C | p.Lys319Gln | p.K319Q | Q5VSY0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-ZJ-AB0I-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
GKAP1 | SNV | Missense_Mutation | novel | c.463N>C | p.Ser155Pro | p.S155P | Q5VSY0 | protein_coding | tolerated(0.07) | benign(0.02) | TCGA-SS-A7HO-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | oxaliplatin | PD |
GKAP1 | SNV | Missense_Mutation | c.365C>A | p.Thr122Lys | p.T122K | Q5VSY0 | protein_coding | deleterious(0.01) | possibly_damaging(0.804) | TCGA-AG-A026-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
GKAP1 | SNV | Missense_Mutation | novel | c.544N>C | p.Lys182Gln | p.K182Q | Q5VSY0 | protein_coding | tolerated(0.42) | benign(0.165) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
GKAP1 | SNV | Missense_Mutation | novel | c.301N>T | p.Pro101Ser | p.P101S | Q5VSY0 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GKAP1 | SNV | Missense_Mutation | novel | c.694N>A | p.Glu232Lys | p.E232K | Q5VSY0 | protein_coding | tolerated(0.48) | benign(0.053) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GKAP1 | SNV | Missense_Mutation | novel | c.129N>C | p.Gln43His | p.Q43H | Q5VSY0 | protein_coding | tolerated(0.09) | benign(0.01) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |